ARTICLE | Product Development
NK cell engagers gain traction on broader bispecifics momentum
NK cell engagers emerge as a budding innate immune modality in immuno-oncology’s second wave
May 1, 2021 2:21 AM UTC
While T cell engagers are flooding pipelines, a growing number of biotechs are betting on the closely-related NK cell engager structure as a safer way to redirect immune cells to tumors.
Pharmas — nearly all of which have jumped on the T cell engager bandwagon — are also testing the waters of the NK cell-targeting counterparts through a spate of recent deals. ...